Artificial intelligence/Machine learning:

• Ohra S, Siddiqui MK, Siddiqui MT, C RR, Gupta J. Quality appraisal of randomized controlled trials using Robins 2.0 tool: A case study on comparing the performance of ChatGPT 4.0 with a human reviewer. Value in Health. 2024; 27(6): S1.

• Ohra S, C RR, Siddiqui MK, Gupta J, Siddiqui MK. Evaluating ChatGPT’s efficacy and efficiency in the risk of bias assessment in health economic evaluations: A comparative analysis using the Drummond checklist. Value in Health. 2024; 27(6): S1.

Cardiovascular diseases:

• Siddiqui MK, Siroula M, Mathur S, Gupta J, Choudhry K. Cardiac manifestations including heart failure and myocardial infarction post covid-19 recovery: A systematic review and meta-analysis. Value in Health. 2023; 26(6): S2.

• Gupta J, Sehgal M, Gupta P. A review of patient registries in heart failure across European Union-5 countries. Value in Health. 2015; 18(7):A341.

• Mazumder D, Arora A, Bhutani MK, Pathak P, Siddiqui MK. Angiotensin receptor blockers and the risk of myocardial infarction: network meta-analysis and probability ranking. Value in Health. 2012; 15(7):A362. 

Dermatology:

• Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis. A meta-analysis. JAMA Dermatology. 2020;156(3):258-269. (Gupta J in Acknowledgments)

Gynaecology and Obstetrics:

• Rajora P, Fernandes S, Gola N, Preethi C, Gupta J, Siddiqui MK. Economic burden associated with post-partum hemorrhage: A targeted literature review. Value in Health. 2024; 27(12): S2.

HTA landscape:

• Divya D, Bhatnagar T, Siddiqui MK, Gupta J. Review of population-adjusted indirect treatment comparison methods in nice non-oncology appraisals. Value in Health. 2023; 26(11): S2.

• Bhatnagar T, Divya D, Gupta J, Siddiqui MK. Shifting landscape of indirect comparison methodologies and their role in informing NICE decision-making processes. Value in Health. 2023; 26(11): S2.

• Divya D, Bhatnagar T, Siroula M, Gupta J, Siddiqui MK. trends of indirect treatment comparison methods use in NICE technology appraisals for hematologic cancers. Value in Health. 2023; 26(11): S2.

• Bhatnagar T, Siroula M, Gupta J, Siddiqui MK, Nielsen SK. Are there any differences in the recommendations for ultra orphan medications: An assessment of NICE, GBA, and HAS. Value in Health. 2023; 26(11): S2.

• Siroula M, Gupta J, Siddiqui MK, Nielsen SK. Understanding the application of various statistical analysis methods to inform comparative effectiveness of ultra orphan treatments: A review of NICE HST guidance. Value in Health. 2023; 26(11): S2.

• Paul K, Rubinstein J, Gupta J, Wahal VP, Zacarelli C, Guill EW. Assessment of the impact of French ATU’s on HAS reimbursement decisions. Value in Health. 2020; 23(5): S1.

• Jaiswal H, Rubinstein J, Gupta J, Wahal VP, Porco P. Key Clinical and Economic Rationales for Oncology Reviews in South Korea. Value in Health Regional Issues. 2020; 22:S21.

• Jaiswal H, Mathur V, Rubinstein J, Gupta J, Wahal VP, et al. Concordance between regulatory and health technology assessments in acute myeloid leukemia across EU5: a comparison of clinical studies. Value in Health. 2020; 23:S60.

• Gupta P, Kumar T, Wahal VP, Adler BN, Gupta J. Use of managed entry agreements in inflammatory disorders among key health technology assessment agencies. Value in Health. 2018; 21:S468.

• Gupta J, Wahal VP. Review of reimbursement decision drivers for rare cancer therapies across EU5 markets. Value in Health. 2017; 20(9):A569.

• Banerjee P, Gupta J, Kumar P, Kapoor A, Mazumder D. Reimbursement decision landscape for metastatic breast cancer therapies: a comparison of factors leading to favorable and unfavorable recommendations across leading HTA agencies. Value in Health. 2015; 18(3):A6.

Immunology/Autoimmune diseases:

• Siddiqui MK, Gupta J. Evolution-RMS trials: Did teriflunomide perform beyond expectations? A predictive meta-analytic testing for teriflunomide 14 mg in relapsing multiple sclerosis. Value in Health. 2024; 27(12): S2.

• Siddiqui MK, Singh B, Attri S, Veraart C, Harty G, & Wong SL. Use of rituximab in adults with relapsing–remitting multiple sclerosis: a systematic literature review. Current Medical Research and Opinion. 2020; 36(5): 809-826.

• Berardi A, Siddiqui MK, Treharne C, Harty G, & Wong SL. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing–remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches. Current Medical Research and Opinion. 2019; 35(8), 1371-1378.

• Siddiqui MK, Khurana IS, Budhia S, Hettle R, Harty G, & Wong SL. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing–remitting multiple sclerosis. Current medical research and opinion. 2018; 34(8): 1361-1371.

• Wong S, Aldridge J, Hettle R, Khurana IS, Siddiqui MK. Analysis of 6-month confirmed disability progression in RRMS patients treated with subcutaneous interferon beta-1a. Neurology. 2018; 90 (15 Supplement).

• Hutchinson M, Fox RJ, Havrdova E, Kurukulasuriya NC, Siddiqui MK, et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison. Current medical research and opinion. 2014; 30(4):613-627.

• Tolley K, Hutchinson M, Pachner A, Kinter ET, Siddiqui MK, et al. Systematic literature review and network meta-analysis of peginterferon beta-1a and injectable therapies for relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. 2014;20:209.

• Tolley K, Hutchinson M, Pachner A, Kinter ET, Siddiqui MK, et al. Systematic literature review and network meta-analysis of pegylated interferon beta-1a and disease modifying therapies for relapsing-remitting multiple sclerosis. Neurology. 2014; 82 (10 Supplement).

Liver diseases:

• Siddiqui MK, Attri S, Orlando M, Lelli F, Maida V, et al. Cost-effectiveness of rifaximin-α versus lactulose for the treatment of recurrent episodes of overt hepatic encephalopathy: a meta-analysis. GastroHep. 2022;3:1-13.

• Younossi Z, Aggarwal P, Shrestha I, Fernandes J, Johansen P, et al. The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes. JHEP Reports. 2022; 4(9):100525

Metabolic diseases:

• Ferdinand KC, Norris KC, Rodbard HW, Trujillo JM. Humanistic and economic burden of patients with cardiorenal metabolic conditions: A systematic review. Diabetes Therapy. 2023; 14(12):1979–1996. (Gupta J in Acknowledgments).

• Chubb B, Gupta P, Gupta J, Nuhoho S, Kallenbach K, Orme M. Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis. Diabetes Ther. 2021;12(5):1325-1339.

• Nuhoho S, Gupta J, Hansen BB, Fletcher-Louis M, Dang-Tan T, Paine A. Orally administered semaglutide versus GLP-1 RAs in patients with type 2 diabetes previously receiving 1-2 oral antidiabetics: systematic review and network meta-analysis. Diabetes Ther. 2019; 10(6):2183-2199.

• Afonso M, Gupta J, Kamra S, Jasso-Mosqueda J. A systematic literature review to identify clinical drivers in cost-effectiveness analyses in T2DM patients uncontrolled on current therapies. Value in Health. 2016; 19(7):A674.

• Jindal R, Gupta J, Arora A, Kaur M, Kumar R, et al. Network Meta-Analysis of Fixed Dose Combination Therapies for the First-Line Treatment of Type 2 Diabetes Mellitus. Value in Health. 2015; 15(7):A660.

• van Acker K, Léger P, Hartemann A, Chawla A, Siddiqui MK. Burden of diabetic foot disorders, guidelines for management and disparities in implementation in Europe: a systematic literature review. Diabetes/Metabolism Research and Reviews. 2014;30(8):635-645.

Oncology:

• Siddiqui MK, Gupta J. Leveraging external priors to address population variability in a network meta-analysis: A case study in advanced esophageal squamous cell carcinoma. Value in Health. 2024; 27(12): S2.

• Siddiqui MK, C RR, Gupta J. Bias reduction in indirect treatment comparison of time-to-event outcomes: A case study on application of ML-NMR versus MAIC using simulated dataset. Value in Health. 2024; 27(12): S2.

• Bonomi PD, Crawford J, Dunne RF, Roeland EJ, Smoyer KE, Siddiqui MK, McRae TD, Rossulek MI, Revkin JH, Tarasenko LC. Mortality burden of pre‐treatment weight loss in patients with non‐small‐cell lung cancer: A systematic literature review and meta‐analysis. Journal of Cachexia, Sarcopenia and Muscle. 2024;15(4):1226–1239.

• Gupta J, Siddiqui MT, Divya D, Siddiqui MK^. Effect of smoking cessation (SC) interventions among people with lung cancer (LC): A systematic literature review. Value in Health. 2023; 26(6): S2.

• Chaudhary MA, Edmondson-Jones M, Baio G, Mackay E, Siddiqui MK, et al. Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up. Medical Decision Making. 2023;43 (1):91-109.

• Bonomi P, Crawford J, Dunne R, Roeland E, Siddiqui MK, et al. The mortality burden of cachexia in patients with non-small cell lung cancer: A meta-analysis. 2023 ASCO Annual Meeting. Abstract #: e24075

• Strosberg J, Leeuwenkamp O, and Siddiqui MK. Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis. Cancer treatment reviews. 2021; 93: 102141.

• Siddiqui MK, Gricar J, Kurt M. Comparative Effectiveness of Docetaxel and Paclitaxel in Advanced Esophageal Squamous Cell Carcinoma Refractory or Intolerant to Previous Chemotherapy: Propensity Score-Matching Analyses from Attraction-3 Trial. Value in Health. 2021; 24: S24.

• Strosberg J, Leeuwenkamp O, and Siddiqui MK. Lu-177-DOTATATE/DOTATOC re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis. Pancreas. 2021; 50(3):452.

• Wu E, Miskala PH, Siddiqui MK, Rai P, Hajdukova E, et al. Pembrolizumab patient reported benefits: A perspective based on multiple tumors. Journal of Clinical Oncology. 2021; 39 (15 suppl): 2650.

• Dalal M, Gupta J, Price K, Zomas A, Miao H, Ashaye A. Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review. Expert Review of Hematology 2020; 13(8):907-922.

• Pandey S, Sharma A, Siddiqui MK, Amadi A. Healthcare costs comparison of nivolumab versus placebo as adjuvant treatment of patients with melanoma: A propensity score matched analysis. Value in Health. 2020;23:S432-S433.

• Pandey S, Sharma A, Siddiqui MK. Extending the network meta-analysis (NMA) framework to multilevel network meta-regression (ML-NMR): A worked example of ML-NMR vs standard NMA. Value in Health. 2020; 23:S407.

• Chaudhary MA, Rafiq S, Siddiqui MK, Vanderpuye-Orgle J, Edmonson-Jones M, et al. Assessing the performance of landmark response analysis to improve overall survival extrapolation in nivolumab NSCLC trials. Value in Health. 2020; 23:S407.

• Rafiq S, Chaudhary MA, Siddiqui MK, Vanderpuye-Orgle J, Edmonson-Jones M, et al. Bayesian MULTI-parameter evidence synthesis to improve long term survival extrapolation with early follow up data from nivolumab NSCLC studies. Value in Health. 2020; 23:S402.

• Mackay E, Chaudhary MA, Vanderpuye-Orgle J, Edmonson-Jones M, Siddiqui MK, et al. Using mixture cure models to improve survival extrapolations from early follow-up data for nivolumab in NSCLC. Value in Health. 2020; 23:S468-S469.

• Shao C, Siddiqui MK, Takyar J, Zhou W, Sen S. Epidemiology and health related quality of life (HRQOL) for advanced cervical cancer: A targeted literature review. Value in Health. 2018; 21:S19.

• Shao C, Siddiqui MK, Takyar J, Zhou W, Sen S. Economic burden of advanced cervical cancer: a systematic literature review. Value in Health. 2018; 21:S27.

• Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta P, Barker C et al. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. Lung cancer. 2017; 112: 200-215.

• Venkatachalam M, Stenehjem D, Parikh ND, Singh P, Siddiqui MK, et al. Cost of treatment-related adverse events (TRAES) in second-line (2L) advanced hepatocellular carcinoma (AHCC): match adjusted indirect comparison (MAIC) of nivolumab and regorafenib. Value in Health. 2017; 20(9):A502-503.

• Siddiqui MK, Fernandes AW, Tyczynski JE, Chawla AS. Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer. Gynecologic Oncology. 2016; 141: 43-44.

Ophthalmology:

• Aggarwal P, Kaur H, Mathur S, Gupta J, Siddiqui MK. A systematic literature review of the humanistic burden associated with geographic atrophy. Value in Health. 2023; 26(11): S2.

• Aggarwal P, Mathur S, Gupta J, Siddiqui MK. Economic burden of geographic atrophy: A systematic review and meta-analysis. Value in Health. 2023; 26(11): S2.

• Siddiqui MK, Mann K, Vonmaltzahn R, Ternouth AM, Verboven Y, et al. Risks and benefits of Acrysof® Cachet™ implantation in high myopia (≥-6 dioptre): A systematic literature review. Value in Health. 2011;14 (7):A261.

Pain management:

• Porter KM, Siddiqui MK, Sharma I, Dickerson S, Eberhardt A. Management of trauma pain in the emergency setting: low-dose methoxyflurane or nitrous oxide? A systematic review and indirect treatment comparison. J Pain Res. 2017;11:11-21.

• Siddiqui MK, Gupta J, Bhutani M, Sehgal M. Opioids in non-malignant pain: are they equivalent in safety profile? A network meta-analysis. Value in Health. 2015; 14(3):A59.

• Datto C, Hellmund R, Siddiqui MK. Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses. Open access rheumatology: research and reviews. 2013; 1-19.

Psychiatry & CNS diseases:

• Velez F, Grinnell T, Siddiqui MK, Blum D. Assessment of eslicarbazepine acetate monotherapy vs. other anti-epileptic drugs for refractory partial-onset seizures: Results of a network meta-analysis using historical-control trials. Neurology. 2016; 86 (16 Supplement).

Rare diseases:

• Mathur S, Premshekar A, Aggarwal P, Gupta J, Siddiqui MK. Global health economic burden of Angelman syndrome: A systematic literature review. Value in Health. 2024; 27(12): S2.

• Mathur S, Aggarwal P, Gupta J, Siddiqui MK, Sharma PSA. Systematic literature review of the humanistic burden associated with Angelman syndrome. Value in Health. 2024; 27(12): S2.

• Mathur S, Premshekar A, Aggarwal P, Gupta J, Siddiqui MK. Advancing therapeutic frontiers for Angelman syndrome: Insights from a systematic review. Value in Health. 2024; 27(12): S2.

• Siddiqui MK, Gupta J, C RR. Use of single arm studies/disconnected observational studies in comparative effectiveness of treatments for Fabry disease: A network meta-analysis using a 3-level hierarchical model. Value in Health. 2024; 27(6): S1.

• Aggarwal P, Kaur H, Mathur S, Gupta J, Siddiqui MK. Humanistic and economic burden of multiple system atrophy: A systematic review. Value in Health. 2023; 26(11): S2.

• Singh B, Sharma A, Mangat G, Pandey S, Siddiqui MK, et al. A meta-analysis of efficacy and safety of vesicular monoamine transporter type 2 inhibitors for treatment of Huntington chorea. Value in Health Regional Issues. 2020; 22:S74.

• Kamat J, Gupta J, Gupta P, Narayanan S. The clinical, humanistic, and economic burden of adenosine deaminase (ADA) severe combined immunodeficiency (SCID): A systematic literature review. Value in Health. 2018; 21:S472.

• Patel R, Kumar J, Gupta J, Narayanan S. Humanistic and economic burden of X-linked hypophosphatemia (XLH): A systematic literature review. Value in Health. 2018; 21:S307.

• Gupta P, Kumar J, Gupta J. Review of rare disease registries across EU5 countries. Value in Health. 2017; 20(9):A571.

• Gupta J, Ghildiyal A. Disease-specific patient-reported outcome instruments in sickle cell disease: A systematic literature review. Value in Health. 2017; 20(9):A561.

Respiratory diseases:

• Preethi C, Gola N, Chaudhary P, Gupta J, Siddiqui MK. Economic burden in patients with systemic scleroderma associated interstitial lung disease: A systematic review. Value in Health. 2024; 27(12): S2.

• Preethi C, Goyal A, Gola N, Gupta J, Siddiqui MK. Clinical significance of Sp-D biomarker in the diagnosis of connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis. Value in Health. 2024; 27(6): S1.

• Preethi C, Siddiqui MK, Gola N, Goyal A, Gupta J. Clinical significance of Kl-6 biomarker in the development of connective tissue disease associated interstitial lung disease: A systematic review and meta-analysis. Value in Health. 2024; 27(6): S1.

• Hurst JR, Han MLK, Singh B, Sharma S, Siddiqui MK, et al. Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review. Respiratory Research. 2022;23 (1):1-23.

• Gibson D, Siddiqui MK, Hurst JR, Stolz D, Verma M, et al. A systematic literature review of factors related to mortality in patients with COPD. Thorax. 2022;77 (Suppl 1):A196.

• Hurst JR, Siddiqui MK, Singh B, Varghese P, Holmgren U, and De Nigris E. A systematic literature review of the humanistic burden of COPD. International Journal of Chronic Obstructive Pulmonary Disease. 2021; 16: 1303-1314.

• Bourdin A, Molinari N, Ferguson GT, Singh B, Siddiqui MK, Holmgren U, and De Nigris E. Efficacy and safety of budesonide/glycopyrronium/formoterol fumarate versus other triple combinations in COPD: a systematic literature review and network meta-analysis. Advances in Therapy. 2021; 38(6): 3089-3112.

• Bourdin A, Husereau D, Molinari N, Golam S, Siddiqui MK, Lindner L, & Xu X. Matching‐adjusted comparison of oral corticosteroid reduction in asthma: Systematic review of biologics. Clinical & Experimental Allergy 50, no. 4 (2020): 442-452.

• Singh B, Sharma S, Kaur G, de Nigris E, Holmgren U, Siddiqui MK. Prognostic risk factors of moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease (COPD): A systematic literature review. Value in Health. 2020;23:S725-S726.

• Bourdin A, Husereau D, Molinari N, Golam S, Siddiqui MK, et al. Systematic review and MAIC of OCS reduction with biologic asthma treatments. European respiratory journal. 2019;54(Suppl 63):PA1658.

• Ferguson GT, Darken P, Ballal S, Siddiqui MK, Singh B, et al. Efficacy of budesonide/glycopyrronium/formoterol fumarate metered dose inhaler (BGF MDI) versus other inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β2-agonist (ICS/LAMA/LABA) triple combinations in COPD: a systematic literature review and network meta-analysis. Advances in therapy. 2020; 37(6): 2956-2975.

• Siddiqui MK, Shukla P, Jenkins M, Ouwens M, Guranlioglu D, Darken P, & Biswas, M. Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β2-agonist fixed-dose combinations in COPD. Therapeutic advances in respiratory disease. 2019; 13: 1753466619894502.

• Sharma N, Singh B, Siddiqui MK, de Nigris E, Holmgren U. Epidemiological burden of moderate-to-very severe COPD: a systematic literature review. European Respiratory Journal. 2019; 54 (suppl 63).

• Bourdin A, Husereau D, Molinari N, Siddiqui MK, Golam S, Linder L, Xu X. Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors: a systematic review. Eur Respir J. 2018; 52(5):1801393.

• Relative efficacy and safety of inhaled glycopyrronium+ formoterol fumarate dihydrate versus other LAMA+ LABA fixed-dose combinations in COPD: A systematic review and bayesian network meta-analysis. Thorax. 2018; 73 (Suppl 4):A233-A234.

Virology/Infections and infestations:

• Pawaskar M, Siddiqui MK, Takyar J, Sharma A, Fergie J. Relative efficacy of varicella vaccines: network meta-analysis of randomized controlled trials. Current Medical Research and Opinion. 2022;38 (10):1772-1782.

• Thommes EW, Kruse M, Kohli M, et al. Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines. Human vaccines & immunotherapeutics. 2017;13(4):867-876. (Gupta J in Acknowledgments)

• Orrskog S, Medin E, Tsolova S, Semenza JC, et al. Causal inference regarding infectious aetiology of chronic conditions: A systematic review. PLoS One. 2013;8(7):e68861. (Gupta J in Acknowledgments)